Key result
Ponatinib exposure was associated with increased reporting odds of 13 cardiac toxicities, most frequently hypertension and coronary artery stenosis.
Why the study?
The study aimed to determine the risk of ponatinib-induced cardiac toxicity, time to onset, and post hoc outcomes.
Does ponatinib increase the risk of cardiac toxicity compared to other drugs in a spontaneous reporting database?
Observational (n=1,772,494)
Does ponatinib increase the risk of cardiac toxicity compared to other drugs in a spontaneous reporting database?
Ponatinib is associated with a significantly increased risk of multiple cardiac toxicities, including hypertension and severe vascular occlusive events, which can occur early or more than a year after treatment initiation.
Answers are grounded in this paper and cite their sources.
Signals warrant closer cardiac monitoring during ponatinib use; hypothesis-generating and require prospective confirmation.
This study aimed to determine the risk of ponatinib-induced cardiac toxicity, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. We analyzed data for the period between April 2004 and March 2021. Data on cardiac toxicities were extracted, and relative risk of adverse events (AEs) was estimated using the reporting odds ratio. We analyzed 1,772,494 reports and identified 1,152 reports of AEs caused by ponatinib. Of these, 163 cardiac toxicities were reportedly associated with ponatinib. Signals were detected for thirteen cardiac toxicities: hypertension, cardiac failure, acute cardiac failure, atrial fibrillation, increased blood pressure, coronary artery stenosis, myocardial infarction, angina pectoris, pulmonary hypertension, prolonged QT on electrocardiography, cardiomyopathy, cardiac dysfunction, and acute myocardial infarction. Among these, hypertension was the most frequently reported AE (27.6%). A histogram of times to onset showed occurrence from 4.5 to 150.5 days. Hypertension, cardiac failure, coronary artery stenosis, and myocardial infarction could potentially result in serious outcomes and some cases occurred earlier or even more than 1 year after starting administration. In conclusion, patients should be monitored for signs of the onset of these AEs not only at the start of ponatinib administration but also over the longer term.
No takes yet. Share an insight, caveat, or question.
Kanbayashi et al. (2022) conducted an observational in Cardiac toxicity (n=1,772,494). Ponatinib vs. All other drugs in the database was evaluated on Reporting odds ratio (ROR) for hypertension (ROR 16.18, 95% CI 11.99-21.83, p=<0.001). Ponatinib exposure was associated with increased reporting odds of 13 cardiac toxicities, most frequently hypertension and coronary artery stenosis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: